投资要点:SW医药生物行业跑输同期沪深300指数。2026年2月13日-2026年2月26日,SW医药生物行业下跌0.95%,跑输同期沪深300指数约1.1个百分点。SW医药生物行业三级细分板块中,多数细分板块均录得正收益,其中其他生物制品和医院板块涨幅居前,分别上涨2.42%和1.80%,医疗研发外包和线下药店板块跌幅居前,分别下跌3.80%和0.65%。行业新闻。2月24日,浙江医保局发布《...
Source Link投资要点:SW医药生物行业跑输同期沪深300指数。2026年2月13日-2026年2月26日,SW医药生物行业下跌0.95%,跑输同期沪深300指数约1.1个百分点。SW医药生物行业三级细分板块中,多数细分板块均录得正收益,其中其他生物制品和医院板块涨幅居前,分别上涨2.42%和1.80%,医疗研发外包和线下药店板块跌幅居前,分别下跌3.80%和0.65%。行业新闻。2月24日,浙江医保局发布《...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.